AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17539886 — intervention group
Group type: EXPERIMENTAL
Intervention: Young maternal age
Number of subjects: 1393
Study 15448290 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance notice letter
Number of subjects: 600
Study 15448290 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 600
Study 15448290 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 600
Study 15448290 — intervention group
Group type: COMPARATOR
Intervention: No letter (control)
Number of subjects: 600
Study 11166973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention
Number of subjects: 253
Study 11166973 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual comparison group
Number of subjects: 253
Study 10188440 — intervention group
Group type: EXPERIMENTAL
Intervention: Philadelphia cervical collar
Number of subjects: 20
Study 10188440 — intervention group
Group type: COMPARATOR
Intervention: Aspen cervical collar
Number of subjects: 20
Study 8091317 — intervention group
Group type: EXPERIMENTAL
Intervention: ZD2138 (350 mg)
Number of subjects: 8
Study 8091317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2456121 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral prostatectomy
Number of subjects: 38
Study 2456121 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 38
Study 28661585 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300)
Number of subjects: 549
Study 28661585 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla‐100)
Number of subjects: 549
Study 28661585 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300) morning injection
Number of subjects: 549
Study 28661585 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla‐100) evening injection
Number of subjects: 549
Study 27389565 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter direct mitral annuloplasty using the Cardioband device
Number of subjects: 45
Study 24038831 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 68
Study 24038831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy
Number of subjects: 68
Study 24038831 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 68
Study 24038831 — intervention group
Group type: EXPERIMENTAL
Intervention: Life event exposure
Number of subjects: 68
Study 22643943 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laryngectomy
Number of subjects: 15
Study 20557511 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks of preoperative albendazole (ABZ) and praziquantel (PZQ)
Number of subjects: 45
Study 20557511 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of preoperative albendazole (ABZ) and praziquantel (PZQ)
Number of subjects: 45
Study 20557511 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of preoperative albendazole (ABZ) and praziquantel (PZQ)
Number of subjects: 45
Study 20557511 — intervention group
Group type: COMPARATOR
Intervention: 0 weeks (control group)
Number of subjects: 45
Study 17573782 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone treatment
Number of subjects: 0
Study 17573782 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15728225 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel six-drug combination chemotherapy for stage III disease
Number of subjects: 503
Study 15728225 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment without alkylating agents for genitourinary nonbladder prostate tumors
Number of subjects: 503
Study 15728225 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment strategy including selective avoidance of local therapy
Number of subjects: 503
Study 15728225 — intervention group
Group type: COMPARATOR
Intervention: Previous treatment strategy (MMT 84)
Number of subjects: 503
Study 15362475 — intervention group
Group type: EXPERIMENTAL
Intervention: Driver re-training sessions
Number of subjects: 65
Study 15362475 — intervention group
Group type: COMPARATOR
Intervention: Waiting (control) group
Number of subjects: 65
Study 15362475 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall driving scores
Number of subjects: 65
Study 15362475 — intervention group
Group type: EXPERIMENTAL
Intervention: Age correlation with driving scores
Number of subjects: 65
Study 10989464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron 5 mg/m2 plus dexamethasone 2-4 mg p.o.
Number of subjects: 438
Study 10989464 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ondansetron 8 mg syrup plus dexamethasone 2-4 mg p.o.
Number of subjects: 438
Study 9185752 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate (OA) 20 g/d, infused intravenously for 4 hours over 7 consecutive days
Number of subjects: 126
Study 9185752 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate (OA) 20 g/d
Number of subjects: 126
Study 9185752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 1588146 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial polysaccharide immune globulin (BPIG) at a dose of 0.5 ml/kg
Number of subjects: 0
Study 1588146 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial polysaccharide immune globulin (BPIG) given at 2, 6, and 10 months of age
Number of subjects: 0
Study 1588146 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent administration of diphtheria‐tetanus‐pertussis or Hib oligosaccharide‐diphtheria CRM197 conjugate vaccines
Number of subjects: 0
Study 3896099 — intervention group
Group type: COMPARATOR
Intervention: Ceruletide (cholecystokinin‐like peptide) administered intramuscularly twice a day for 4 consecutive days to schizophrenic patients.
Number of subjects: 15
Study 3896099 — intervention group
Group type: COMPARATOR
Intervention: Ceruletide (0.3 micrograms/kg or 0.6 micrograms/kg) administered intramuscularly to normal volunteers.
Number of subjects: 15
Study 3896099 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo administered intramuscularly to normal volunteers.
Number of subjects: 15
Study 3269259 — intervention group
Group type: COMPARATOR
Intervention: Carbon monoxide exposure at 0 ppm
Number of subjects: 23
Study 3269259 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide exposure at 50 ppm
Number of subjects: 23
Study 3269259 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide exposure at 100 ppm
Number of subjects: 23
Study 3269259 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide exposure at 150 ppm
Number of subjects: 23
Study 3269259 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide exposure (all levels)
Number of subjects: 23
Study 3269259 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxyhemoglobin concentrations
Number of subjects: 23
Study 31795820 — intervention group
Group type: EXPERIMENTAL
Intervention: Video with animated pictographs
Number of subjects: 187
Study 31795820 — intervention group
Group type: COMPARATOR
Intervention: Video with static pictographs
Number of subjects: 187
Study 31795820 — intervention group
Group type: COMPARATOR
Intervention: Audiobooklet with static pictographs
Number of subjects: 187
Study 31219772 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 20
Study 27539717 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% acyclovir cream (test product T)
Number of subjects: 40
Study 27539717 — intervention group
Group type: COMPARATOR
Intervention: 5% acyclovir cream (reference product R)
Number of subjects: 40
Study 25050610 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2,000IU.d‐1)
Number of subjects: 55
Study 25050610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 23380890 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 26
Study 20889359 — intervention group
Group type: EXPERIMENTAL
Intervention: Active local treatment (injection/hydroelectrophoresis)
Number of subjects: 124
Study 20889359 — intervention group
Group type: COMPARATOR
Intervention: Placebo local treatment
Number of subjects: 124
Study 20889359 — intervention group
Group type: EXPERIMENTAL
Intervention: Active local treatment (days 8 and 11) requested by placebo group
Number of subjects: 124
Study 20889359 — intervention group
Group type: EXPERIMENTAL
Intervention: Active therapy at 3-week follow-up
Number of subjects: 124
Study 19745651 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight conversion to DVP ER
Number of subjects: 16
Study 19745651 — intervention group
Group type: COMPARATOR
Intervention: Gradual conversion to DVP ER
Number of subjects: 16
Study 16233932 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (1200 mg m(‐2) day(‐1))
Number of subjects: 26
Study 16233932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12065742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 32-7315 (2.5 mg/kg, i.p., twice daily)
Number of subjects: 11
Study 12065742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 32-7315 (5 mg/kg, i.p., twice daily)
Number of subjects: 11
Study 12065742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 32-7315 (10 mg/kg, i.p., twice daily)
Number of subjects: 11
Study 12065742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 32-7315 (20 mg/kg, i.p., twice daily)
Number of subjects: 11
Study 12065742 — intervention group
Group type: COMPARATOR
Intervention: Ro 32-7315 (450 mg, oral, single dose)
Number of subjects: 11
Study 12065742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 32-7315 (dose-dependent)
Number of subjects: 11
Study 12065742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 32-7315 (IC50)
Number of subjects: 11
Study 12065742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 32-7315 (cellular assay)
Number of subjects: 11
Study 10404085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide/methotrexate/fluorouracil (CMF)
Number of subjects: 274
Study 7751529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray 0.06%, 84 micrograms per nostril three times a day for the first 6 months, with possible dose reduction in the last 6 months.
Number of subjects: 96
Study 7751529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray 0.06%
Number of subjects: 96
Study 7751529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray
Number of subjects: 96
Study 2301192 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug bulletin on renal colic treatment
Number of subjects: 186
Study 2301192 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug bulletin on irritable bowel syndrome (IBS) treatment
Number of subjects: 186
Study 6772011 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg of elemental zinc as zinc acetate per day)
Number of subjects: 22
Study 6772011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31837906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ondansetron 0.1 mg/kg plus ketamine 4 mg/kg
Number of subjects: 121
Study 31837906 — intervention group
Group type: COMPARATOR
Intervention: Ketamine 4 mg/kg (control group)
Number of subjects: 121
Study 28887269 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion-enhanced behaviors during death pronouncement
Number of subjects: 92
Study 28887269 — intervention group
Group type: COMPARATOR
Intervention: Standard death pronouncement without compassion-enhanced behaviors
Number of subjects: 92
Study 27388820 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryton Side Branch Stent
Number of subjects: 133
Study 27388820 — intervention group
Group type: COMPARATOR
Intervention: Standard provisional SB stenting (from TRYTON Pivotal RCT)
Number of subjects: 133
Study 26641838 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI more than 30 kg/m
Number of subjects: 139
Study 26641838 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in MVC over 3 months
Number of subjects: 139
Study 23623914 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sodium nitrite (NaNO₂) (1.5 μmol/min for 20 min)
Number of subjects: 29
Study 23623914 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 29
Study 23623914 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sodium nitrite (NaNO₂) before ischemia
Number of subjects: 29
Study 23623914 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sodium nitrite (NaNO₂) during reperfusion
Number of subjects: 29
Study 20652481 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with reduced protein content
Number of subjects: 1678
Study 20652481 — intervention group
Group type: COMPARATOR
Intervention: Infant formula with higher protein content
Number of subjects: 1678
Study 18990175 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5/10 mg
Number of subjects: 863
Study 18990175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 863
Study 17158411 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise therapy (treatment group)
Number of subjects: 27
Study 17158411 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 27
Study 14574034 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 14574034 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 0
Study 14574034 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study 14574034 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide
Number of subjects: 0
Study 14574034 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dofetilide, oral bolus-flecainide, propafenone, intravenous ibutilide
Number of subjects: 0
Study 14574034 — intervention group
Group type: COMPARATOR
Intervention: Rate control drugs
Number of subjects: 0
Study 10717333 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan at intravenous doses of 1.5 mg/m(2)/day over 30 min for 5 days every 3 weeks (Arm A)
Number of subjects: 0
Study 10717333 — intervention group
Group type: COMPARATOR
Intervention: Topotecan at intravenous doses of 1.3 mg/m(2) for 5 days every 3 weeks (Arm B)
Number of subjects: 0
Study 10717333 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A (1.5 mg/m(2)/day)
Number of subjects: 0
Study 10717333 — intervention group
Group type: COMPARATOR
Intervention: Arm B (1.3 mg/m(2))
Number of subjects: 0
Study 8872288 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise (HI; 85% of peak VO2)
Number of subjects: 186
Study 8872288 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise (LO; 50% of peak VO2)
Number of subjects: 186
Study 1677368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (high dose: 4 micrograms/kg/min)
Number of subjects: 45
Study 1677368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (intermediate dose: 2 micrograms/kg/min)
Number of subjects: 45
Study 1677368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (low dose: 1 microgram/kg/min)
Number of subjects: 45
Study 1677368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 6137386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 0.5 mg
Number of subjects: 12
Study 6137386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 1 mg
Number of subjects: 12
Study 6137386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 2 mg
Number of subjects: 12
Study 31867608 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (0.2 mJ/mm2) once a week for four weeks in addition to standard physical rehabilitation (n = 12)
Number of subjects: 38
Study 31867608 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin‐A injection (0.5-2 U/kg/muscle group with maximum dose of 12 U/kg/body weight) once at entry besides standard physical rehabilitation (n = 13)
Number of subjects: 38
Study 31867608 — intervention group
Group type: COMPARATOR
Intervention: Standard physical rehabilitation (control group; n = 13)
Number of subjects: 38
Study 31365529 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mL of 4% articaine with 1:100,000 epinephrine
Number of subjects: 90
Study 31365529 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 mL of 4% articaine with 1:100,000 epinephrine
Number of subjects: 90
Study 31365529 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mL of PDL injection
Number of subjects: 90
Study 31365529 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 mL of PDL injection
Number of subjects: 90
Study 29673271 — intervention group
Group type: EXPERIMENTAL
Intervention: Beyond Silence (6 in-person, 2-hour sessions plus 5 online sessions)
Number of subjects: 192
Study 29673271 — intervention group
Group type: COMPARATOR
Intervention: Mental Health First Aid (standardized 2-day training program)
Number of subjects: 192
Study 27054365 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheterization threshold of 500 ml
Number of subjects: 721
Study 27054365 — intervention group
Group type: COMPARATOR
Intervention: Catheterization threshold of 800 ml
Number of subjects: 721
Study 24597730 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional lesions in the interpulmonary isthmus (group II, n = 38)
Number of subjects: 76
Study 24597730 — intervention group
Group type: COMPARATOR
Intervention: No further ablation (group I, n = 38)
Number of subjects: 76
Study 22155768 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (qHPV vaccine; Gardasil)
Number of subjects: 4065
Study 20388140 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 17
Study 20388140 — intervention group
Group type: COMPARATOR
Intervention: Soy protein (control)
Number of subjects: 17
Study 18489430 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted dosage
Number of subjects: 13219
Study 18489430 — intervention group
Group type: COMPARATOR
Intervention: Medical staff dosage
Number of subjects: 13219
Study 16197758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler
Number of subjects: 40
Study 16197758 — intervention group
Group type: COMPARATOR
Intervention: Hand-activated scaling instruments
Number of subjects: 40
Study 12803269 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol 2 mg
Number of subjects: 90
Study 12803269 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 20 mg
Number of subjects: 90
Study 12803269 — intervention group
Group type: COMPARATOR
Intervention: saline 2 mL
Number of subjects: 90
Study 10368895 — intervention group
Group type: EXPERIMENTAL
Intervention: Neovir (interferonogenic immunomodulator)
Number of subjects: 32
Study 10368895 — intervention group
Group type: COMPARATOR
Intervention: Routine complex treatment
Number of subjects: 32
Study 8616033 — intervention group
Group type: COMPARATOR
Intervention: Conventional maintenance (arm A)
Number of subjects: 358
Study 8616033 — intervention group
Group type: COMPARATOR
Intervention: More intensive regimen (arm B)
Number of subjects: 358
Study 8616033 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 358
Study 1599352 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose therapy with norfloxacin (800 mg)
Number of subjects: 156
Study 1599352 — intervention group
Group type: COMPARATOR
Intervention: 3-day therapy with norfloxacin (400 mg twice daily)
Number of subjects: 156
Study 1599352 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 156
Study 6327800 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate (200 or 400 mg oral dose)
Number of subjects: 20
Study 6327800 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate (600-1000 mg/day, long-term administration)
Number of subjects: 20
Study 31492603 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylated gelatin infusion (10 ml/kg)
Number of subjects: 0
Study 31492603 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate infusion
Number of subjects: 0
Study 31492603 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylated gelatin infusion
Number of subjects: 0
Study 29557399 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mm long implants
Number of subjects: 80
Study 29557399 — intervention group
Group type: COMPARATOR
Intervention: 10.0 mm long implants
Number of subjects: 80
Study 27144672 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative RT with TST/NMES therapy (Group II)
Number of subjects: 30
Study 27144672 — intervention group
Group type: COMPARATOR
Intervention: Post-operative RT alone (Group I)
Number of subjects: 30
Study 27144672 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-radiated muscle)
Number of subjects: 30
Study 25035200 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured voice rehabilitation with a speech-language pathologist
Number of subjects: 69
Study 25035200 — intervention group
Group type: COMPARATOR
Intervention: Control group (no voice rehabilitation)
Number of subjects: 69
Study 23234816 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorella group (C. vulgaris extract 1200 mg/day + metformin 750 mg/day + vitamin E 200 mg/day for 3 months)
Number of subjects: 76
Study 23234816 — intervention group
Group type: COMPARATOR
Intervention: Metformin group (metformin 1250 mg/day + vitamin E 200 mg/day for 3 months)
Number of subjects: 76
Study 23234816 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorella group
Number of subjects: 76
Study 20879960 — intervention group
Group type: EXPERIMENTAL
Intervention: Matsuda Index for NFG
Number of subjects: 78
Study 20879960 — intervention group
Group type: EXPERIMENTAL
Intervention: Matsuda Index for IFG
Number of subjects: 78
Study 20879960 — intervention group
Group type: EXPERIMENTAL
Intervention: Matsuda Index for diabetes
Number of subjects: 78
Study 20879960 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposition Index for NFG
Number of subjects: 78
Study 20879960 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposition Index for IFG
Number of subjects: 78
Study 20879960 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposition Index for diabetes
Number of subjects: 78
Study 20879960 — intervention group
Group type: EXPERIMENTAL
Intervention: Matsuda Index differences between tests for NFG
Number of subjects: 78